Tirzepatide: Mechanism of Action

Introduction

Tirzepatide (LY3298176) is a synthetic dual incretin receptor agonist designed to engage both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Published research has characterized its molecular pharmacology, receptor binding profile, and downstream signaling in considerable detail across in vitro, preclinical, and large-scale clinical study settings. This article summarizes findings from the peer-reviewed literature on tirzepatide's reported mechanism of action; a full listing of published trials is available in the tirzepatide published research article.

Receptor Targets and Binding Profile

Tirzepatide was designed to engage two class B G protein-coupled receptors: GIPR and GLP-1R. Both receptors are expressed in pancreatic beta cells and in multiple other tissues, and both couple primarily through stimulatory G proteins (Gs) to activate adenylyl cyclase and elevate intracellular cyclic adenosine monophosphate (cAMP).

The seminal pharmacological characterization by Willard and colleagues (2020) in JCI Insight reported that tirzepatide displays distinct potency and efficacy profiles at the two receptor subtypes [1]. At the GIPR, tirzepatide behaved as a full agonist, closely mimicking the actions of native GIP. At the GLP-1R, tirzepatide displayed approximately fivefold weaker binding affinity compared to native GLP-1, with reduced potency in Gs-mediated cAMP generation relative to the endogenous ligand [1]. The authors described this profile as "imbalanced," with the GIPR component dominant — a characterization that has informed ongoing scientific discussion about how each receptor contributes to tirzepatide's observed pharmacological profile.

Biased Agonism at the GLP-1 Receptor

A pharmacologically distinctive feature of tirzepatide documented in the 2020 JCI Insight study is biased agonism at the GLP-1R: at this receptor, tirzepatide preferentially stimulated cAMP accumulation over beta-arrestin 1 recruitment, relative to native GLP-1 [1]. Biased agonism refers to the capacity of a ligand to selectively stabilize receptor conformations that preferentially activate one downstream signaling pathway over another.

The functional significance of this bias was examined in the same study. The authors reported that beta-arrestin 1 limited the insulin secretory response to native GLP-1 stimulation, but not to GIP or tirzepatide stimulation, suggesting that tirzepatide's bias away from beta-arrestin recruitment at the GLP-1R may be associated with a relatively sustained insulin secretory response [1]. This mechanistic distinction from selective GLP-1R agonists has been a subject of active scientific interest.

The structural basis of tirzepatide's dual receptor engagement was characterized by Sun and colleagues in a 2022 cryo-electron microscopy study published in the Proceedings of the National Academy of Sciences [2]. That study identified the molecular contact points governing tirzepatide's interaction with both the GIPR and GLP-1R complexes and reported that tirzepatide adopted structurally distinct binding poses at each receptor — findings that offer an atomic-resolution framework for understanding the imbalanced pharmacology described by Willard et al.

Reported Downstream Effects

Published research has reported a range of downstream pharmacological effects associated with tirzepatide's dual receptor engagement across preclinical models and clinical study populations.

The foundational 2018 paper by Coskun and colleagues reported that tirzepatide administration in preclinical models was associated with glucose-dependent insulin secretion, reduced food intake, and changes in body weight [3]. The authors characterized effects on body composition as more pronounced than those observed with selective GLP-1R agonists in the same models and attributed these differences to the additive contribution of GIPR co-engagement.

In the SURPASS-1 phase 3 clinical trial — a 40-week, double-blind, placebo-controlled study in adults with type 2 diabetes managed by diet and exercise alone — Rosenstock and colleagues (2021) reported statistically significant reductions in glycated hemoglobin (HbA1c) and body weight across all three tirzepatide dose groups compared with placebo at 40 weeks [4]. The low incidence of hypoglycemia across treatment groups was consistent with the glucose-dependent insulin secretory mechanism attributed to incretin receptor agonism.

The SURPASS-2 trial (Frías et al., 2021) compared tirzepatide to semaglutide — a selective GLP-1 receptor agonist — in a 40-week, randomized, open-label study in adults with type 2 diabetes on background metformin [5]. The authors reported that tirzepatide at all three doses studied produced greater mean reductions in HbA1c and body weight than semaglutide at its comparator dose, meeting prespecified noninferiority and superiority criteria. Whether the differential effects observed reflect GIPR co-agonism, the biased GLP-1R pharmacology, or the interaction of both has been a subject of ongoing scientific discussion and continued investigation.

Gastrointestinal effects — including nausea, vomiting, and diarrhea — were reported in participants in the SURPASS trials and were consistent with the known pharmacology of GLP-1R agonism. The authors noted these events were generally transient and dose-related [4,5].

Areas of Ongoing Investigation

Several aspects of tirzepatide's mechanism represent active frontiers in the published literature.

The relative contribution of GIPR agonism versus GLP-1R agonism to tirzepatide's observed clinical profile has not been fully resolved. The imbalanced agonist profile characterized by Willard et al. (2020) [1] makes direct mechanistic comparison with selective GLP-1R agonists complex, and this question continues to motivate basic pharmacology research.

The role of GIPR signaling in adipose tissue, the central nervous system, and other peripheral organs beyond the pancreas has been an active area of basic research, with preclinical findings informing hypotheses about tissue-level mechanisms. Translation of these findings to clinical populations represents a research frontier that ongoing studies continue to address. Research-grade tirzepatide from SpartaLabs is supplied with batch-specific HPLC and mass spectrometry documentation for non-clinical investigation.

References

1. Willard FS, Douros JD, Gabe MBN, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMID: 32730231. DOI: 10.1172/jci.insight.140532

2. Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci USA. 2022;119(13):e2116506119. PMID: 35333651. DOI: 10.1073/pnas.2116506119

3. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. DOI: 10.1016/j.molmet.2018.09.009

4. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. DOI: 10.1016/S0140-6736(21)01324-6

5. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647. DOI: 10.1056/NEJMoa2107519